受强制性开放获取政策约束的文章 - Scott J Antonia了解详情
无法在其他位置公开访问的文章：7 篇
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
S Antonia, SB Goldberg, A Balmanoukian, JE Chaft, RE Sanborn, A Gupta, ...
The lancet oncology 17 (3), 299-308, 2016
强制性开放获取政策： US National Institutes of Health
Soft tissue sarcoma
GD Demetri, S Antonia, RS Benjamin, MM Bui, ES Casper, EU Conrad, ...
Journal of the National Comprehensive Cancer Network 8 (6), 630-674, 2010
强制性开放获取政策： US National Institutes of Health
Survivin dendritic cell vaccine safely induces immune responses and is associated with durable disease control after autologous transplant in patients with myeloma
CL Freeman, R Atkins, I Varadarajan, M Menges, J Edelman, R Baz, ...
Clinical Cancer Research 29 (22), 4575-4585, 2023
强制性开放获取政策： US National Institutes of Health
Hepatic portal venous gas in a patient with metastatic non-small cell lung cancer on bevacizumab therapy: a case report and review of the literature
J Ortega, JM Hayes, S Antonia
Cancer chemotherapy and pharmacology 65, 187-190, 2009
强制性开放获取政策： US National Institutes of Health
Dose-limiting pulmonary toxicity in a phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab followed by Nivolumab for patients with stage 3 Unresectable Non-small Cell …
CL Liveringhouse, K Latifi, AG Asous, NB Lam, SA Rosenberg, TJ Dilling, ...
International Journal of Radiation Oncology* Biology* Physics 116 (4), 837-848, 2023
强制性开放获取政策： US National Institutes of Health
Immune checkpoint inhibitors in the aged
J Isaacs, S Antonia, J Clarke
Current Oncology Reports 23, 1-6, 2021
强制性开放获取政策： US National Institutes of Health
Patient-reported distress and clinical outcomes with immuno-oncology agents in metastatic non-small cell lung cancer (mNSCLC): a real-world retrospective cohort study
MH Bodd, SC Locke, SP Wolf, S Antonia, J Crawford, J Hartman, ...
Lung Cancer 175, 17-26, 2023
强制性开放获取政策： US National Institutes of Health
可在其他位置公开访问的文章：117 篇
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ...
New England Journal of Medicine 366 (26), 2443-2454, 2012
强制性开放获取政策： US National Institutes of Health
Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer
H Borghaei, L Paz-Ares, L Horn, DR Spigel, M Steins, NE Ready, ...
New England Journal of Medicine 373 (17), 1627-1639, 2015
强制性开放获取政策： US National Institutes of Health
Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer
J Brahmer, KL Reckamp, P Baas, L Crinò, WEE Eberhardt, ...
New England Journal of Medicine 373 (2), 123-135, 2015
强制性开放获取政策： US National Institutes of Health
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Yokoi, ...
New England Journal of Medicine 377 (20), 1919-1929, 2017
强制性开放获取政策： Cancer Research UK
Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC
SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Kurata, ...
New England Journal of Medicine 379 (24), 2342-2350, 2018
强制性开放获取政策： US National Institutes of Health
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase …
NA Rizvi, J Mazières, D Planchard, TE Stinchcombe, GK Dy, SJ Antonia, ...
The lancet oncology 16 (3), 257-265, 2015
强制性开放获取政策： US National Institutes of Health
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
SJ Antonia, JA López-Martin, J Bendell, PA Ott, M Taylor, JP Eder, ...
The Lancet Oncology 17 (7), 883-895, 2016
强制性开放获取政策： Cancer Research UK
Overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer
SN Gettinger, L Horn, L Gandhi, DR Spigel, SJ Antonia, NA Rizvi, ...
Journal of clinical oncology 33 (18), 2004-2012, 2015
强制性开放获取政策： US National Institutes of Health
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
MD Hellmann, NA Rizvi, JW Goldman, SN Gettinger, H Borghaei, ...
The lancet oncology 18 (1), 31-41, 2017
强制性开放获取政策： US National Institutes of Health
Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer
MD Hellmann, T Nathanson, H Rizvi, BC Creelan, F Sanchez-Vega, ...
Cancer cell 33 (5), 843-852. e4, 2018
强制性开放获取政策： US National Institutes of Health, Cancer Research UK, Wellcome Trust
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
L Chen, DL Gibbons, S Goswami, MA Cortez, YH Ahn, LA Byers, X Zhang, ...
Nature communications 5 (1), 5241, 2014
强制性开放获取政策： US National Institutes of Health, 国家自然科学基金委员会
Nivolumab versus docetaxel in previously treated patients with advanced non–small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials …
L Horn, DR Spigel, EE Vokes, E Holgado, N Ready, M Steins, ...
Journal of clinical oncology 35 (35), 3924-3933, 2017
强制性开放获取政策： US National Institutes of Health
Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
DR Spigel, C Faivre-Finn, JE Gray, D Vicente, D Planchard, L Paz-Ares, ...
Journal of Clinical Oncology 40 (12), 1301-1311, 2022
强制性开放获取政策： US National Institutes of Health, National Institute for Health Research, UK
出版信息和资助信息由计算机程序自动确定